Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kber LV, Lawson FC, Ping L, Wei X, Lewis EF
By activating additional receptors, dual and triple agonists can tap into a broader set of levers at once, offering the chance for greater weight reduction, improved glycemic control, and (possibly) fewer side effects compared to GLP-1 monotherapy
Although there is evidence that ghrelin and GLP-1 modulate reward responses in humans as well (Decarie-Spain & Kanoski, 2021), this has not been systematically reviewed before
The mechanism behind that finding is the key to interpreting it
10.1111/jcmm.16963 8 BeattyA.SinghT.TyurinaY
Com isto, ser redirecionado para ti anncios de produtos de teu interesse, e isto vai permitir que compres um produto por um preo significativamente reduzido